SEARCH:   Advanced

Blood, 1 July 2005, Vol. 106, No. 1, pp. 353-355. Prepublished online as a Blood First Edition Paper on March 10, 2005; DOI 10.1182/blood-2005-01-0033. This Article Full Text (PDF) All Versions of this Article: 2005-01-0033v1 106/1/353    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chang, H. Articles by Trudel, S. Search for Related Content PubMed PubMed Citation Articles by Chang, H. Articles by Trudel, S. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 13, 2005 Accepted March 2, 2005 Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma Hong Chang*, A K Stewart, Xiao Ying Qi, Zhi Hua Li, Qi Long Yi, and Suzanne Trudel Department of Laboratory Hematology, Princess Margaret Hospital/University Health Network, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, Princess Margaret Hospital/University Health Network, Toronto, Canada Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, Toronto, Canada; McLaughlin Center for Molecular Medicine, University of Toronto, Toronto, Canada Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, Toronto, Canada Department of Biostatistics, Princess Margaret Hospital/University Health Network, Toronto, Canada * Corresponding author; email: hong.chang{at}uhn.on.ca. The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). As t(4;14) uniquely results in FGFR3 expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3 and its expression was correlated with the t(4;14) status. FISH detected t(4;14) in 16 (19%) of 85 MM patient specimens and immunocytochemistry detected aberrant FGFR3 expression in 13 (15%). Twelve (75%) t(4;14) positive cases expressed FGFR3 and 12 (92%) FGFR3 positive cases harbored a t(4;14). FGFR3 expression and t(4;14) were strongly correlated (p< 0.0001). FGFR3 expression by immunohistochemistry was associated with the IgA isotype (p=0.0059), a shorter progression free survival (median 11.5 vs. 25.8 months, p=0.0172) and a shorter overall survival (median 19.2 vs 46.3 months, p=0.0309). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. A. Dawson, S. S. Opat, Y. Taouk, M. Donovan, M. Zammit, K. Monaghan, N. Horvath, A. W. Roberts, H. M. Prince, M. Hertzberg, et al. Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma Clin. Cancer Res., January 15, 2009; 15(2): 714 - 722. [Abstract] [Full Text] [PDF] J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] E. Masih-Khan, S. Trudel, C. Heise, Z. Li, J. Paterson, V. Nadeem, E. Wei, D. Roodman, J. O. Claudio, P. L. Bergsagel, et al. MIP-1{alpha} (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma Blood, November 15, 2006; 108(10): 3465 - 3471. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020